文献速递造血干细胞移植与细胞治疗血栓与止血

干细胞移植后早发性VOD/SOS的发病率与危险因素在年轻与年长成人中不同

Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation.
PubMed 文献 · Blood Adv · 2024-01-01

该单中心回顾性分析纳入1561例接受异基因造血干细胞移植的成人患者,其中72%使用移植后环磷酰胺预防GVHD。年龄≤25岁者VOD发生率为16.8%(20/119),高于>25岁者的3.8%(55/1442),且两年龄组VOD预测因素不同。

要点

  • 年龄≤25岁患者移植后VOD发生率为16.8%(20/119),>25岁者为3.8%(55/1442)。
  • 在18至25岁患者中,高/极高DRI者VOD发生率为31%,低/中DRI者为12%(P = .03)。
  • 在18至25岁患者中,既往化疗线数>1者VOD发生率为24%,≤1者为6%(P = .03)。

核心结论

  • 接受allo-SCT的年轻(≤25岁)与年长(>25岁)成人患者VOD发病率及预测因素存在差异。

研究设计与样本

  • 回顾性单中心分析,纳入1561例年龄≥18岁接受allo-SCT的成人患者,72%使用移植后环磷酰胺作为GVHD预防。

主要发现

  • 年龄≤25岁患者VOD发生率为16.8%(20/119),>25岁患者为3.8%(55/1442)。
  • 多变量分类与回归树分析确认年龄是VOD发生率的首要独立决定因素。
  • 在18至25岁患者中,高/极高DRI者VOD发生率为31%,低/中DRI者为12%(P = .03)。
  • 在18至25岁患者中,既往化疗线数>1者VOD发生率为24%,≤1者为6%(P = .03)。
  • 在>25岁患者中,大多数危险因素对应的VOD发生率在3%至5%之间,仅肝脏因素(基线胆红素、天冬氨酸转氨酶、丙氨酸转氨酶升高)或吉妥珠单抗暴露与VOD发生率升高相关。

关键数值与推荐

  • 年龄≤25岁患者VOD发生率为16.8%(20/119),>25岁患者为3.8%(55/1442)。
  • 18至25岁患者中,高/极高DRI者VOD发生率为31%,低/中DRI者为12%(P = .03)。
  • 18至25岁患者中,既往化疗线数>1者VOD发生率为24%,≤1者为6%(P = .03)。
  • 接受PTCy者与接受其他GVHD预防者的VOD发生率无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Veno-occlusive disease (VOD) is a rare but potentially life-threatening complication after allogeneic hematopoietic stem cell transplantation (allo-SCT). Although increasing awareness and modern transplant techniques have mitigated risk, the interaction of historic risk factors in the current era with posttransplant cyclophosphamide (PTCy) is unknown. We performed a retrospective single-center analysis of adult patients aged ≥18 years undergoing allo-SCT (N = 1561) using predominately PTCy as graft-versus-host disease (GVHD) prophylaxis (72%). We found a higher rate of VOD at 16.8% (20 of 119) in those aged ≤25 years compared with 3.8% (55 of 1442) in those aged >25 years, with unique predictors of VOD within each cohort. Multivariate classification and regression tree (CART) analysis confirmed age as the primary independent determinant of the rate of VOD. Among patients aged 18 to 25 years, disease risk index (DRI; 31% with high/very high DRI vs 12% low/intermediate DRI; P = .03) and prior lines of chemotherapy (24% with >1 vs 6% with ≤1; P = .03) were the strongest predictors of VOD. Incidence of VOD in patients aged >25 years of age consistently ranged between 3% and 5% across most risk factors evaluated, with only hepatic factors (baseline elevation of bilirubin, aspartate transferase, alanine aminotransferase) or gemtuzumab exposure associated with increased rates of VOD. There was no significant difference in rates of VOD in those receiving PTCy compared with those receiving alternate GVHD prophylaxis. Our data highlight the differences in incidence and predictors of VOD between younger (≤25) and older (>25) adults undergoing allo-SCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Marcoux C, Saliba RM, Wallis W, et al. Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Adv. 2024. PMID: 38266155. doi:10.1182/bloodadvances.2023011233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。